Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 1 de 1
Filtre
Ajouter des filtres








Gamme d'année
1.
Rev. méd. Chile ; 133(6): 667-673, jun. 2005. graf
Article Dans Espagnol | LILACS | ID: lil-429121

Résumé

Background: Erectile dysfunction is a public health problem. Millions of men worldwide experience this condition, affecting their quality of life. Sildenafil, a phosphodiesterase type 5 inhibitor, is the treatment of choice for erectile dysfunction. Aim: To study the characteristics of Sildenafil use among costumers of community pharmacies in Concepcion Chile. Material and methods: A structured interview about Sildenafil use was applied to subjects purchasing the drug in community pharmacies and that consented to participate. Results: One hundred thirty eight males were studied. Forty six percent of patients were fifty years old or older. Most (47.1%) used Sildenafil for one year or more and 60.5% had no adverse events. Among those experiencing side effects, headache was experienced by 38.9%, flushing by 16.6% and gastrointestinal effects by 16.7%. Ninety percent of patients had a good evaluation of the drug in terms of benefits and tolerance. Thirty two percent of the subjects, had diseases associated to erectile dysfunction. Among these, 45% had diabetes mellitus, 29.5% had hypertension, and 18.2% had prostatic diseases. In 54% of cases, the drug was prescribed by a physician. Twenty two percent of patients experienced changes in the effect of the drug when it was simultaneously used with other drugs or meals. Thirty four percent of patients used other drugs. Among these, 43.3% were using antihypertensives, and 26.7% were using antidiabetic drugs. Conclusions: Considering the elevated age and the number of associated disease of patients using Sildenafil, the use of the drug under medical prescription must be emphasized to avoid untoward effects.


Sujets)
Adulte , Humains , Mâle , Adulte d'âge moyen , Dysfonctionnement érectile/traitement médicamenteux , Inhibiteurs de la phosphodiestérase/usage thérapeutique , Pipérazines/usage thérapeutique , Vasodilatateurs/usage thérapeutique , Facteurs âges , Chili , Services des pharmacies communautaires , Interactions médicamenteuses , Dysfonctionnement érectile/étiologie , Entretiens comme sujet , Inhibiteurs de la phosphodiestérase/effets indésirables , Pipérazines/effets indésirables , Polypharmacie , Purines , Facteurs de risque , Sulfones , Vasodilatateurs/effets indésirables
SÉLECTION CITATIONS
Détails de la recherche